EUVIMEDOpdag EUVIMED
KohortenstudieOpen access · CC BY 4.0

Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden

Qing Liu, Omid Sadr-Azodi, Lars Engstrand iD, Katja Fall, Nele Brusselaers iD

Helicobacter · 2024

DOI: 10.1111/hel.70001 ↗

At a glance

Kohortenstudie in Helicobacter, 2024. Written by Qing Liu and 4 co-authors. Institution: Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Colorectal Neoplasms, Helicobacter Infections, Helicobacter pylori. Cited 19 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY 4.0). Funded by: China Scholarship Council, Vetenskapsrådet.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Helicobacter pylori ( H. pylori ) is an established gastric carcinogen, also associated with an increased risk of colorectal cancer. Therefore, we suspected that H. pylori eradication lowers the risk of colorectal cancer. Material and Methods We assessed if H. pylori eradication therapy is associated with a reduced risk of colorectal adenocarcinoma in a population‐based nationwide cohort study. This study included all Swedish adults with at least one recorded H. pylori eradication episode between July 2005 and December 2012, based on the high‐quality Swedish health registries. Colorectal adenocarcinoma risks were compared to the Swedish background population, presented as standardized incidence ratios (SIRs) and 95% confidence intervals (CIs), accounting for age, sex, calendar period, tumor location (left or right sided), stage, and number of eradication episodes, from 1 year after eradication and onward.

Results

Among 80,381 individuals receiving H. pylori eradication therapy (average follow‐up 4.1 years), 282 were diagnosed with colorectal cancer (97.2% adenocarcinoma). Overall, H. pylori eradication was associated with an elevated risk of colorectal adenocarcinoma (SIR 1.27, 95% CI: 1.12–1.43). The colorectal adenocarcinoma risk was increased 1–2 years after eradication (SIR 1.42, 95% CI: 1.17–1.72), then decreased 2–4 years (SIR 0.80, 95% CI: 0.65–0.98) and 4–6 years (SIR 0.76, 95% CI: 0.57–0.99), yet not ≥ 6 years (SIR 1.36, 95% CI: 0.78–2.21) after eradication compared to the general population. Overall, right‐sided (SIR 1.47, 95% CI: 1.21–1.76) and left‐sided (SIR 1.35, 95% CI: 1.09–1.67) colon adenocarcinomas risks were higher among eradicated individuals than the general population.

Conclusion

H. pylori eradication was not associated with a clear and consistent reduction of colorectal cancer in our Swedish cohort.

Subjects

MeSH terms (MEDLINE)

Colorectal NeoplasmsHelicobacter InfectionsHelicobacter pyloriHumansSwedenMaleFemaleMiddle AgedAgedCohort StudiesAdultAdenocarcinomaAnti-Bacterial AgentsIncidenceAged, 80 and overYoung AdultAdolescent

Author keywords

Helicobacter pylori eradication therapyantibioticscancer riskcolorectal adenocarcinomaproton pump inhibitors

Substances

Anti-Bacterial Agents

Authors and institutions

  • Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Surgery, Capio Saint Göran Hospital, Stockholm, Sweden.
  • Clinical Epidemiology and Biostatistics School of Medical Sciences, Örebro University, Örebro, Sweden.
  • Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Global Health Institute, University of Antwerp, Antwerp, Belgium.

ORCID profiles: Lars Engstrand, Nele Brusselaers

Funding

  • China Scholarship Council
  • Vetenskapsrådet

Cite

APA

Liu, Q., Sadr-Azodi, O., Engstrand, L., Fall, K., & Brusselaers, N. (2024). Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden. Helicobacter. https://doi.org/10.1111/hel.70001

Vancouver

Liu Q, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden. Helicobacter. 2024. doi:10.1111/hel.70001

BibTeX
@article{Liu2024,
  author = {Liu, Qing and Sadr-Azodi, Omid and Engstrand, Lars and Fall, Katja and Brusselaers, Nele},
  title = {Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.70001}
}
Start for free →